Statement re. Silicon Valley Bank

March 13, 2023
Verici Dx plc (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, is aware of public statements and media reports relating to Silicon Valley Bank (“SVB”). The Company does not hold any cash at SVB nor does it have any banking relationship with SVB.   Enquiries: About Verici Dx plc Verici Dx is […]
Keep Reading

Verici Dx achieves CLIA Certificate of Compliance for full commercial launch of Tutivia™

March 2, 2023
Successful CMS review and inspection solidify commercial positioning and represents a major milestone toward US Medicare reimbursement
Keep Reading

Product rebranding as TutiviaTM

November 1, 2022
Verici Dx’s post-transplant test, Tuteva, to be rebranded as TutiviaTM Verici Dx plc (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, announces that its post-transplant blood test focused on acute rejection, has been rebranded as TutiviaTM. TutiviaTM (formerly known as Tuteva), is a blood-based RNA signature for a risk score for acute […]
Keep Reading

Half-year report

September 7, 2022
Strong data in validation study for Tuteva™ paving the way for commercial launch
Keep Reading

Positive results for Clarava™ from blinded multi-centre clinical validation study

September 6, 2022
Data validates Clarava’s ability to identify patients likely to experience future kidney transplant rejection
Keep Reading

Result of AGM and voting results

June 28, 2022
Verici DX announces that at the Annual General Meeting
Keep Reading

Distribution of Verici Dx shares by EKF Diagnostics Holdings plc

June 20, 2022
Verici DX notes the announcement made by EKF Diagnostics Holdings PLC
Keep Reading

Investor Update

June 16, 2022
Sara Barrington, CEO, will provide a live presentation relating to positive data from the Tuteva™ clinical validation study via the Investor Meet Company platform
Keep Reading
1 2 3 6

BRR Media

November 3, 2020
In this interview, Sara Barrington, CEO of Verici Dx, is joined by BRR Media to discuss the background of Verici Dx and where the company is moving towards in the future.

Keep Reading

Proactive Investors

November 3, 2020
Sara Barrington, CEO of Verici Dx, Joins Proactive to discuss Verici's listing on AIM after raising £14.5m to progress with transplant clinical tests.
Keep Reading

Vox Markets

November 3, 2020
Enjoy this informative interview with Paul Hill from Vox Markets, along with Sara Barrington and Barbara Murphy from Verici Dx. In it they discuss the function of the kidneys, What Verici Dx is, and much more.
Keep Reading